MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$2.52 - HK$8.46
Previous CloseN/A
Volume546.00K
Average Volume (3M)8.07M
Market Cap
HK$3.69B
Enterprise ValueHK$1.18B
Total Cash (Recent Filing)HK$1.32B
Total Debt (Recent Filing)HK$279.62M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.68
Price to Sales (P/S)4.13
P/FCF Ratio-5.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$2.15B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthAn 81.74% equity ratio and minimal leverage (0.04 D/E) provide durable financial resilience. Low debt reduces default and interest risks, giving management flexibility to fund product development and commercialization from internal or equity sources during multi‑year adoption cycles.
Revenue Growth TrendConsistent revenue growth (7.54% y/y) indicates ongoing market adoption of its interventional devices. Durable top-line expansion supports scale benefits, improves bargaining power with hospitals, and creates a foundation for margin recovery if cost structure and mix are improved over the medium term.
Recurring Consumables Business ModelA consumables-heavy device model creates repeatable procedure-linked revenue from an installed base. This structural demand and repeat purchase pattern improve revenue visibility and customer stickiness over time, supporting long-term cash flow potential if operational profitability is achieved.
Bears Say
Persistent UnprofitabilitySustained negative EBIT and net losses weaken the firm's ability to generate returns and reinvest internally. Extended unprofitability risks continual equity dilution or external funding needs, constraining strategic initiatives and reducing resilience to setbacks during multi‑year commercialization efforts.
Weak Cash GenerationZero operating and free cash flow indicate the business currently does not self‑fund operations or growth. This structural cash shortfall raises execution risk for clinical trials, sales expansion, and inventory buildup, increasing reliance on external financing and pressuring long‑term sustainability.
Negative Return On EquityA negative ROE shows capital is not producing shareholder returns, signaling inefficient use of equity. Over time this undermines investor confidence, may force capital raises or strategy shifts, and limits the company's ability to build long‑term shareholder value without a clear path to profitability.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$2.52 and its highest was HK$8.46 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$3.69B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Sep 02, 2026 which is in 149 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
Currently, no data Available
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.21%
12-Months-Change
Fundamentals
Return on Equity
0.22%
Trailing 12-Months
Asset Growth
8.90%
Trailing 12-Months
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
Technical Analysis
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
Yestar Healthcare Holdings Co Ltd
―
Venus Medtech (Hangzhou), Inc. Class H
―
Options Prices
Currently, No data available
---